Bayer has led a $25m series B round for Medopad, which allows patients to capture healthcare data through smartphones and watches.
UK-based health technology developer Medopad has gained $25m in a series B round led by pharmaceutical and chemicals group Bayer, TechCrunch reported yesterday.
Infrastructure and services conglomerate NWS Holdings and venture capital firm Healthbox filled out the round, which reportedly valued Medopad at $200m to $300m post-money.
Medopad operates a platform for patients to capture healthcare data through devices such as smartphones and watches, sharing the information with physicians in real time.
The company is working on artificial intelligence-based methods…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
